Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.74 |
| ▸ | GSR | P00390 | 1/20 | 0.52 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | GABRR1 | P24046 | 3/20 | 0.44 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8536227 | 0.97 | CPB2 (0.71) | CPB2GSRRNPEPHDAC1HDAC2 | |
| SCHEMBL14453643 | 0.95 | CPB2 (0.68) | CPB2GSRRNPEPHDAC1HDAC2 | |
| SCHEMBL9817605 | 0.90 | CPB2 (0.68) | CPB2GSRRNPEPHDAC1HDAC2 | |
| SCHEMBL23611202 | 0.90 | CPB2 (0.69) | CPB2GSRRNPEPHDAC1HDAC2 | |
| SCHEMBL264890 | 0.90 | CPB2 (0.76) | CPB2GSRRNPEPHDAC1HDAC2 | |
| SCHEMBL27816843 | 0.89 | CPB2 (0.61) | CPB2GSRRNPEPHDAC1HDAC2 | |
| SCHEMBL9747951 | 0.89 | CHRM1 (0.70) | CPB2GSRRNPEPHDAC1HDAC2 | |
| SCHEMBL27581250 | 0.87 | CPB2 (0.65) | CPB2GSRRNPEPCA2MAPK1 | |
| Hydrochloric Acid SCHEMBL8420827 | 0.87 | CHRM1 (0.67) | CPB2GSRRNPEPHDAC1HDAC2 | |
| Hydrochloric Acid SCHEMBL12491698 | 0.85 | CPB2 (0.64) | CPB2GSRRNPEPFOLH1GABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527880-B2 | Cyanine-based telodendrimers and uses for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-20 | — | — | US | claimed |
| US-20250000811-A1 | TELODENDRIMER NANOCARRIERS FOR MONOMERIC AMPHOTERICIN B DELIVERY | UNIV NEW YORK STATE RES FOUND (US) | 2025-01-02 | — | — | US | claimed |
| CN-118649242-A | Application of amphiphilic dendritic polypeptide in oral delivery of peptide drugs | 上海胜普泽泰医药科技有限公司 | 2024-09-17 | — | — | CN | claimed |
| CN-118620025-A | Amphiphilic dendritic polypeptide molecule, synthesis method thereof and self-assembly method | 厦门大学 | 2024-09-10 | — | — | CN | claimed |
| US-11649326-B2 | Functional, segregated, charged telodendrimers and nanocarriers and methods of making and using same | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-05-16 | — | — | US | claimed |
| US-20230076792-A1 | SEQUENTIAL TARGETING IN CROSSLINKING NANO-THERANOSTICS FOR TREATING BRAIN TUMORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-03-09 | — | — | US | claimed |
| CN-115551917-A | Sequential targeting of cross-linked nanotherapeutics for the treatment of brain tumors | 加利福尼亚大学董事会 | 2022-12-30 | — | — | CN | claimed |
| EP-4077477-A1 | SEQUENTIAL TARGETING IN CROSSLINKING NANO-THERANOSTICS FOR TREATING BRAIN TUMORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-10-26 | — | — | EP | claimed |
| US-11406714-B2 | Telodendrimers and nanocarriers and methods of using same | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-08-09 | — | — | US | claimed |
| EP-3347053-B1 | FUNCTIONAL, SEGREGATED, CHARGED TELODENDRIMERS AND NANOCARRIERS AND METHODS OF MAKING AND USING SAME | THE RESEARCH FOUNDATION FOR STATE UNIV OF NEW YORK (US) | 2022-05-25 | — | — | EP | claimed |
| US-20140161719-A1 | PORPHYRIN MODIFIED TELODENDRIMERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-06-12 | — | — | US | claimed |
| CN-103748142-A | Reversibly crosslinked micelle systems | UNIV CALIFORNIA | 2014-04-23 | — | — | CN | claimed |
| EP-2707419-A2 | REVERSIBLY CROSSLINKED MICELLE SYSTEMS | The Regents of the University of California (US) | 2014-03-19 | — | — | EP | claimed |
| WO-2013096388-A1 | TELODENDRIMERS WITH ENHANCED DRUG DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-06-27 | — | — | WO | claimed |
| CN-102159189-B | Nanocarriers for drug delivery | UNIV CALIFORNIA | 2013-06-12 | — | — | CN | claimed |
| WO-2012158622-A2 | REVERSIBLY CROSSLINKED MICELLE SYSTEMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-11-22 | — | — | WO | claimed |
| US-20110286915-A1 | Nanocarriers for Drug Delivery | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-24 | — | — | US | claimed |
| CN-102159189-A | Nanocarriers for drug delivery | UNIV CALIFORNIA | 2011-08-17 | — | — | CN | claimed |
| EP-2344134-A2 | NANOCARRIERS FOR DRUG DELIVERY | The Regents of the University of California (US) | 2011-07-20 | — | — | EP | claimed |
| WO-2010039496-A2 | NANOCARRIERS FOR DRUG DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-04-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140161719-A1 | PORPHYRIN MODIFIED TELODENDRIMERS | CETP, NR1H4, ABCB4 | CPB2 685/4885GSR 225/4885RNPEP 2046/4885 |
| US-20110286915-A1 | Nanocarriers for Drug Delivery | CLTA, EPCAM, EGFR | CPB2 3615/4885GSR 1966/4885RNPEP 3519/4885 |
| US-12527880-B2 | Cyanine-based telodendrimers and uses for treating cancer | TUBB1, CA13, YWHAZ | CPB2 1490/4885GSR 2934/4885RNPEP 1971/4885 |
| US-20230076792-A1 | SEQUENTIAL TARGETING IN CROSSLINKING NANO-THERANOSTICS FOR TREATING BRAIN TUMORS | TIE1, CA12, CA13 | CPB2 2940/4885GSR 1099/4885RNPEP 3233/4885 |
| US-11406714-B2 | Telodendrimers and nanocarriers and methods of using same | TTI2, MTCL3, HTT | CPB2 3709/4885GSR 223/4885RNPEP 2278/4885 |
| US-11649326-B2 | Functional, segregated, charged telodendrimers and nanocarriers and methods of making and using same | TSPO, TBCA, TTI2 | CPB2 2883/4885GSR 1515/4885RNPEP 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.